Sarepta Therapeutics, Inc. (SRPT)
USD 51.38
(-5.6%)
USD 51.38
(-5.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.36 Billion USD | 2.38% |
| 2022 | 1.32 Billion USD | 26.05% |
| 2021 | 1.05 Billion USD | 1.31% |
| 2020 | 1.04 Billion USD | 22.95% |
| 2019 | 846.57 Million USD | 38.68% |
| 2018 | 610.46 Million USD | 110.19% |
| 2017 | 290.44 Million USD | 6.77% |
| 2016 | 272.02 Million USD | 22.84% |
| 2015 | 221.43 Million USD | 54.26% |
| 2014 | 143.54 Million USD | 37.36% |
| 2013 | 104.5 Million USD | 55.9% |
| 2012 | 67.03 Million USD | -19.16% |
| 2011 | 82.91 Million USD | 64.67% |
| 2010 | 50.35 Million USD | 52.16% |
| 2009 | 33.09 Million USD | -14.71% |
| 2008 | 38.79 Million USD | -12.0% |
| 2007 | 44.09 Million USD | 33.22% |
| 2006 | 33.09 Million USD | 48.42% |
| 2005 | 22.3 Million USD | -12.46% |
| 2004 | 25.47 Million USD | 28.38% |
| 2003 | 19.84 Million USD | -24.2% |
| 2002 | 26.17 Million USD | 62.51% |
| 2001 | 16.1 Million USD | 34.74% |
| 2000 | 11.95 Million USD | 42.32% |
| 1999 | 8.4 Million USD | 3.7% |
| 1998 | 8.1 Million USD | 80.0% |
| 1997 | 4.5 Million USD | 60.71% |
| 1996 | 2.8 Million USD | 3.7% |
| 1995 | 2.7 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 328 Million USD | 0.01% |
| 2024 Q2 | 310.36 Million USD | -5.38% |
| 2023 Q2 | 360.63 Million USD | 1.14% |
| 2023 FY | 1.36 Billion USD | 2.38% |
| 2023 Q4 | 327.98 Million USD | 3.91% |
| 2023 Q1 | 356.57 Million USD | 6.61% |
| 2023 Q3 | 315.63 Million USD | -12.48% |
| 2022 FY | 1.32 Billion USD | 26.05% |
| 2022 Q4 | 334.46 Million USD | 3.98% |
| 2022 Q3 | 321.67 Million USD | -20.93% |
| 2022 Q1 | 266.26 Million USD | -3.36% |
| 2022 Q2 | 406.82 Million USD | 52.79% |
| 2021 FY | 1.05 Billion USD | 1.31% |
| 2021 Q1 | 266.45 Million USD | -9.2% |
| 2021 Q2 | 312.14 Million USD | 17.15% |
| 2021 Q3 | 200.42 Million USD | -35.79% |
| 2021 Q4 | 275.53 Million USD | 37.48% |
| 2020 Q3 | 265.97 Million USD | 1.37% |
| 2020 Q2 | 262.37 Million USD | 19.76% |
| 2020 FY | 1.04 Billion USD | 22.95% |
| 2020 Q1 | 219.07 Million USD | -28.12% |
| 2020 Q4 | 293.45 Million USD | 10.33% |
| 2019 Q4 | 304.76 Million USD | 45.41% |
| 2019 Q2 | 180.87 Million USD | 19.52% |
| 2019 Q3 | 209.59 Million USD | 15.88% |
| 2019 Q1 | 151.33 Million USD | -28.16% |
| 2019 FY | 846.57 Million USD | 38.68% |
| 2018 Q2 | 172.44 Million USD | 92.11% |
| 2018 FY | 610.46 Million USD | 110.19% |
| 2018 Q4 | 210.64 Million USD | 50.63% |
| 2018 Q3 | 139.84 Million USD | -18.9% |
| 2018 Q1 | 89.76 Million USD | 16.76% |
| 2017 Q4 | 76.87 Million USD | 21.65% |
| 2017 FY | 290.44 Million USD | 6.77% |
| 2017 Q1 | 55.33 Million USD | -40.94% |
| 2017 Q2 | 94.97 Million USD | 71.64% |
| 2017 Q3 | 63.19 Million USD | -33.46% |
| 2016 Q3 | 56.53 Million USD | -8.96% |
| 2016 FY | 272.02 Million USD | 22.84% |
| 2016 Q1 | 59.7 Million USD | -9.14% |
| 2016 Q4 | 93.68 Million USD | 65.72% |
| 2016 Q2 | 62.1 Million USD | 4.02% |
| 2015 Q3 | 51.76 Million USD | 22.93% |
| 2015 FY | 221.43 Million USD | 54.26% |
| 2015 Q1 | 61.86 Million USD | 38.24% |
| 2015 Q2 | 42.1 Million USD | -31.93% |
| 2015 Q4 | 65.7 Million USD | 26.93% |
| 2014 FY | 143.54 Million USD | 37.36% |
| 2014 Q2 | 32.85 Million USD | 5.27% |
| 2014 Q1 | 31.2 Million USD | -12.03% |
| 2014 Q3 | 34.73 Million USD | 5.72% |
| 2014 Q4 | 44.74 Million USD | 28.83% |
| 2013 Q2 | 20.03 Million USD | 0.75% |
| 2013 Q1 | 19.88 Million USD | 12.35% |
| 2013 Q3 | 29.1 Million USD | 45.23% |
| 2013 Q4 | 35.47 Million USD | 21.9% |
| 2013 FY | 104.5 Million USD | 55.9% |
| 2012 Q3 | 14.47 Million USD | -13.63% |
| 2012 FY | 67.03 Million USD | -19.16% |
| 2012 Q2 | 16.76 Million USD | -7.31% |
| 2012 Q1 | 18.08 Million USD | -19.92% |
| 2012 Q4 | 17.7 Million USD | 22.27% |
| 2011 Q2 | 21.71 Million USD | 9.5% |
| 2011 FY | 82.91 Million USD | 64.67% |
| 2011 Q3 | 18.79 Million USD | -13.43% |
| 2011 Q4 | 22.58 Million USD | 20.16% |
| 2011 Q1 | 19.82 Million USD | 14.89% |
| 2010 Q3 | 12.49 Million USD | 7.16% |
| 2010 Q2 | 11.66 Million USD | 30.47% |
| 2010 Q1 | 8.94 Million USD | -1.7% |
| 2010 Q4 | 17.25 Million USD | 38.07% |
| 2010 FY | 50.35 Million USD | 52.16% |
| 2009 Q3 | 9.27 Million USD | 15.77% |
| 2009 FY | 33.09 Million USD | -14.71% |
| 2009 Q1 | 6.71 Million USD | -19.81% |
| 2009 Q2 | 8.01 Million USD | 19.29% |
| 2009 Q4 | 9.09 Million USD | -1.92% |
| 2008 Q4 | 8.37 Million USD | -24.62% |
| 2008 FY | 38.79 Million USD | -12.0% |
| 2008 Q2 | 9.86 Million USD | 4.29% |
| 2008 Q1 | 9.45 Million USD | -12.89% |
| 2008 Q3 | 11.1 Million USD | 12.65% |
| 2007 Q3 | 11.42 Million USD | 2.09% |
| 2007 Q1 | 10.62 Million USD | 20.84% |
| 2007 FY | 44.09 Million USD | 33.22% |
| 2007 Q4 | 10.85 Million USD | -4.99% |
| 2007 Q2 | 11.19 Million USD | 5.37% |
| 2006 Q3 | 7.28 Million USD | -2.04% |
| 2006 Q2 | 7.43 Million USD | -22.4% |
| 2006 Q1 | 9.58 Million USD | 51.6% |
| 2006 FY | 33.09 Million USD | 48.42% |
| 2006 Q4 | 8.78 Million USD | 20.64% |
| 2005 Q1 | 5.59 Million USD | 7.05% |
| 2005 Q4 | 6.32 Million USD | 21.6% |
| 2005 Q3 | 5.19 Million USD | 0.23% |
| 2005 Q2 | 5.18 Million USD | -7.2% |
| 2005 FY | 22.3 Million USD | -12.46% |
| 2004 Q1 | 7.85 Million USD | 7.66% |
| 2004 Q3 | 5.13 Million USD | -29.39% |
| 2004 Q4 | 5.22 Million USD | 1.76% |
| 2004 Q2 | 7.26 Million USD | -7.44% |
| 2004 FY | 25.47 Million USD | 28.38% |
| 2003 Q3 | 5.09 Million USD | 37.07% |
| 2003 Q2 | 3.71 Million USD | -0.61% |
| 2003 Q1 | 3.73 Million USD | -13.46% |
| 2003 FY | 19.84 Million USD | -24.2% |
| 2003 Q4 | 7.29 Million USD | 43.19% |
| 2002 Q4 | 4.32 Million USD | -22.88% |
| 2002 Q1 | 8.13 Million USD | 61.79% |
| 2002 Q2 | 8.11 Million USD | -0.17% |
| 2002 Q3 | 5.6 Million USD | -30.99% |
| 2002 FY | 26.17 Million USD | 62.51% |
| 2001 Q3 | 3.65 Million USD | -5.67% |
| 2001 Q1 | 3.55 Million USD | -2.82% |
| 2001 Q2 | 3.87 Million USD | 8.87% |
| 2001 Q4 | 5.02 Million USD | 37.63% |
| 2001 FY | 16.1 Million USD | 34.74% |
| 2000 FY | 11.95 Million USD | 42.32% |
| 2000 Q2 | 3.05 Million USD | 24.74% |
| 2000 Q1 | 2.44 Million USD | 11.15% |
| 2000 Q3 | 2.79 Million USD | -8.2% |
| 2000 Q4 | 3.65 Million USD | 30.71% |
| 1999 Q4 | 2.2 Million USD | -4.35% |
| 1999 FY | 8.4 Million USD | 3.7% |
| 1999 Q1 | 1.8 Million USD | -30.77% |
| 1999 Q3 | 2.3 Million USD | 15.0% |
| 1999 Q2 | 2 Million USD | 11.11% |
| 1998 Q2 | 1.9 Million USD | 11.76% |
| 1998 Q3 | 2 Million USD | 5.26% |
| 1998 FY | 8.1 Million USD | 80.0% |
| 1998 Q4 | 2.6 Million USD | 30.0% |
| 1998 Q1 | 1.7 Million USD | 41.67% |
| 1997 Q1 | 800 Thousand USD | 9.59% |
| 1997 Q3 | 1 Million USD | -33.33% |
| 1997 FY | 4.5 Million USD | 60.71% |
| 1997 Q4 | 1.2 Million USD | 20.0% |
| 1997 Q2 | 1.5 Million USD | 87.5% |
| 1996 Q3 | 600 Thousand USD | 1.69% |
| 1996 FY | 2.8 Million USD | 3.7% |
| 1996 Q1 | 430 Thousand USD | 0.0% |
| 1996 Q4 | 730 Thousand USD | 21.67% |
| 1996 Q2 | 590 Thousand USD | 37.21% |
| 1995 FY | 2.7 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -394.425% |
| Alkermes plc | 996.24 Million USD | -36.594% |
| Agenus Inc. | 78.18 Million USD | -1640.554% |
| Aptorum Group Limited | 10.56 Thousand USD | -12879106.89% |
| Ardelyx, Inc. | 169.93 Million USD | -700.777% |
| Dyadic International, Inc. | 9.15 Million USD | -14767.936% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -6015.207% |
| Lantern Pharma Inc. | 17.87 Million USD | -7511.868% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -20114.324% |
| Novavax, Inc. | 779.12 Million USD | -74.66% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -1578.736% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -1555.576% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -6907.832% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -4496.423% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -2461.471% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -257.643% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -5498.548% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -3493.485% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -4322.401% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -1506.328% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -7695.251% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -707.913% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -4059.612% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -751.644% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 24.402% |
| AlloVir, Inc. | 180.93 Million USD | -652.111% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -205.296% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -4484.654% |
| Bicycle Therapeutics plc | 216.92 Million USD | -527.33% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -691.624% |
| ChromaDex Corporation | 56.37 Million USD | -2313.695% |
| Chimerix, Inc. | 93.38 Million USD | -1357.149% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -9683.265% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -803.981% |
| CRISPR Therapeutics AG | 463.49 Million USD | -193.6% |
| Precision BioSciences, Inc. | 92.46 Million USD | -1371.742% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -435.662% |
| Fortress Biotech, Inc. | 200.19 Million USD | -579.746% |
| Fortress Biotech, Inc. | 200.19 Million USD | -579.746% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -4055.674% |
| ImmuCell Corporation | 9.61 Million USD | -14049.587% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -762.292% |
| Immix Biopharma, Inc. | 16.14 Million USD | -8330.751% |
| Incyte Corporation | 1.19 Billion USD | -14.307% |
| Innoviva, Inc. | 132.15 Million USD | -929.721% |
| IO Biotech, Inc. | 91.44 Million USD | -1388.159% |
| Jaguar Health, Inc. | 42.01 Million USD | -3138.884% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -703.9% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -1513.815% |
| ContextLogic Inc. | 387 Million USD | -251.632% |
| MiMedx Group, Inc. | 229.72 Million USD | -492.363% |
| MEI Pharma, Inc. | 34.78 Million USD | -3812.08% |
| NextCure, Inc. | 67.63 Million USD | -1911.942% |
| Onconetix, Inc. | 34.9 Million USD | -3798.359% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -10576.424% |
| Opthea Limited | 191.96 Million USD | -608.879% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -49355.75% |
| Vaxcyte, Inc. | 468.04 Million USD | -190.747% |
| PDS Biotechnology Corporation | 43.04 Million USD | -3061.365% |
| Precigen, Inc. | 84.18 Million USD | -1516.537% |
| Pharming Group N.V. | 225.49 Million USD | -503.491% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -710.845% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -1775.282% |
| PureTech Health plc | 144.59 Million USD | -841.11% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -944.669% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -455.078% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -5498.548% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -495.075% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -4309.79% |
| Acelyrin, Inc. | 422.06 Million USD | -222.42% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -10553777.773% |
| Summit Therapeutics Inc. | 87.68 Million USD | -1451.92% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -3571.533% |
| Senti Biosciences, Inc. | 94.7 Million USD | -1336.901% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -1001.403% |
| Elevation Oncology, Inc. | 45.44 Million USD | -2894.426% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -4517.792% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -34420.559% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -929.557% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -3892.422% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -16002.438% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -650.584% |
| Seer, Inc. | 110.49 Million USD | -1131.62% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1827.667% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -1355.762% |
| ESSA Pharma Inc. | 32.13 Million USD | -4134.806% |
| GlycoMimetics, Inc. | 39.28 Million USD | -3363.935% |
| GT Biopharma, Inc. | 13.57 Million USD | -9923.696% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -519.032% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -576.636% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -424.551% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -2297.535% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -2416.304% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -13593.556% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -237.201% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -7089.059% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -2584.428% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -424.079% |
| Aptose Biosciences Inc. | 52.35 Million USD | -2499.162% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -9343.315% |
| Soligenix, Inc. | 7.79 Million USD | -17357.0% |
| Century Therapeutics, Inc. | 56.07 Million USD | -2326.953% |
| Kura Oncology, Inc. | 165.8 Million USD | -720.738% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -1088.414% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -16257.94% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -54735.413% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -1163.549% |
| Autolus Therapeutics plc | 196.72 Million USD | -591.732% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -1507.448% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -1068.555% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -6920.673% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -322.932% |
| GRI Bio, Inc. | 11.33 Million USD | -11910.741% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -19186.772% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -937.263% |
| IGM Biosciences, Inc. | 265.59 Million USD | -412.373% |
| INmune Bio, Inc. | 29.89 Million USD | -4451.836% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -688.633% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -3275.518% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -8416.091% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -8544.744% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -2091.402% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -1165.617% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -393.599% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -351.422% |
| Verastem, Inc. | 92.08 Million USD | -1377.8% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -7485.801% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -632.705% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -1020.872% |
| Histogen Inc. | 14.27 Million USD | -9434.872% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -8379.592% |
| Surrozen, Inc. | 18.55 Million USD | -7235.941% |
| Organovo Holdings, Inc. | 14.91 Million USD | -9023.815% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -26633.869% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -2180.451% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -5205.95% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -2794.986% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -17728.442% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -663.92% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -2708.822% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -455.426% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -8755.695% |
| Apollomics, Inc. | 54.14 Million USD | -2413.515% |
| Amarin Corporation plc | 272.35 Million USD | -399.645% |
| Mesoblast Limited | 5.9 Million USD | -22956.879% |
| Turnstone Biologics Corp. | 78.33 Million USD | -1637.11% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -457.433% |
| Synaptogenix, Inc. | 8.31 Million USD | -16268.065% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -9229.611% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -437.753% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -3982.85% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -15309.136% |
| Exelixis, Inc. | 1.58 Billion USD | 14.24% |
| Better Therapeutics, Inc. | 38.26 Million USD | -3456.576% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -486.433% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -59.122% |
| NLS Pharmaceutics AG | 11.8 Million USD | -11425.449% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -16821.573% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -4437.115% |
| Gritstone bio, Inc. | 148.37 Million USD | -817.153% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1876.18% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -8217.841% |
| Avid Bioservices, Inc. | 25.99 Million USD | -5134.717% |
| Insmed Incorporated | 949.26 Million USD | -43.355% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -8573.266% |
| MediWound Ltd. | 18.86 Million USD | -7112.301% |
| OmniAb, Inc. | 83.89 Million USD | -1522.048% |
| Alector, Inc. | 248.8 Million USD | -446.948% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -480.781% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -2504.385% |
| Zai Lab Limited | 547.47 Million USD | -148.562% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -241.353% |
| Aura Biosciences, Inc. | 84.99 Million USD | -1501.131% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -450.63% |
| Immunic, Inc. | 99.22 Million USD | -1271.473% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -755.795% |
| Veracyte, Inc. | 357.93 Million USD | -280.188% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 84.906% |
| FibroGen, Inc. | 398.11 Million USD | -241.817% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -9476.474% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -19656.496% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -18997.224% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 58.201% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -5159.603% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -329.9% |
| TG Therapeutics, Inc. | 198.47 Million USD | -585.636% |
| Galecto, Inc. | 35.62 Million USD | -3719.623% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -3244.435% |
| Fortrea Holdings Inc. | 457.3 Million USD | -197.576% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -2407.124% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -4612.297% |
| XBiotech Inc. | 37.51 Million USD | -3527.878% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1876.18% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -6490.232% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -857.91% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -1273.522% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -1129.106% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | -42.011% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -4617.688% |
| Vaxxinity, Inc. | 56.05 Million USD | -2327.819% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -215.999% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -6000.044% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -1127.432% |
| NexImmune, Inc. | 28.16 Million USD | -4731.158% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -24503.685% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -7505.512% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 51.664% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -5245.131% |
| Scopus BioPharma Inc. | 11.71 Million USD | -11516.144% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -970.987% |
| Ainos, Inc. | 12.95 Million USD | -10406.079% |
| Pluri Inc. | 22.48 Million USD | -5953.456% |
| Prothena Corporation plc | 282.4 Million USD | -381.865% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -580.334% |
| Celularity Inc. | 215.05 Million USD | -532.767% |
| Rallybio Corporation | 78.93 Million USD | -1624.037% |
| Cue Biopharma, Inc. | 19.54 Million USD | -6863.55% |
| MeiraGTx Holdings plc | 151.07 Million USD | -800.738% |
| Omeros Corporation | 94.75 Million USD | -1336.203% |
| Humacyte, Inc. | 23.49 Million USD | -5691.45% |
| Immunocore Holdings plc | 308.04 Million USD | -341.766% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -40042.094% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -1466.588% |
| Blueprint Medicines Corporation | 722.86 Million USD | -88.254% |
| CalciMedica, Inc. | 21.81 Million USD | -6137.416% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -1722.686% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -747.65% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -694.429% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -361.388% |
| Pulmatrix, Inc. | 22.03 Million USD | -6074.866% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -3835.841% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -1431.313% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -146.719% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -1775.67% |
| Cytokinetics, Incorporated | 173.61 Million USD | -683.827% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -3853.68% |
| Nutriband Inc. | 5.73 Million USD | -23632.292% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -3020.21% |
| Vor Biopharma Inc. | 126.03 Million USD | -979.705% |
| Roivant Sciences Ltd. | 1.18 Billion USD | -14.433% |
| Evogene Ltd. | 27.79 Million USD | -4796.787% |
| ProKidney Corp. | 151.52 Million USD | -798.099% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -1734.603% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -17590.772% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -121.55% |
| CorMedix Inc. | 48.95 Million USD | -2679.572% |
| BioLineRx Ltd. | 50.8 Million USD | -2578.668% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -802.997% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -3474.325% |
| Atai Life Sciences N.V. | 125.78 Million USD | -981.86% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -1566.865% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -1571.581% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -438.826% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -4056.436% |
| MediciNova, Inc. | 10.9 Million USD | -12384.256% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -956.371% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -18645.265% |
| GeoVax Labs, Inc. | 6.02 Million USD | -22496.777% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -185.67% |
| Biomea Fusion, Inc. | 126.13 Million USD | -978.858% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | -3.734% |
| Mereo BioPharma Group plc | 35.84 Million USD | -3696.711% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -612.138% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -491.778% |
| Absci Corporation | 73.66 Million USD | -1747.28% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -4833.714% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -918.652% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -461.945% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -419.301% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -554.258% |
| Allakos Inc. | 196.05 Million USD | -594.096% |
| Imunon, Inc. | 20.31 Million USD | -6600.091% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -1099.285% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -269.173% |
| BioAtla, Inc. | 129.68 Million USD | -949.309% |
| NLS Pharmaceutics AG | 11.8 Million USD | -11425.449% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -8489.39% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -1502.507% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -3158.817% |
| XOMA Corporation | 46.46 Million USD | -2828.819% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -1124.076% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -855.207% |
| aTyr Pharma, Inc. | 12.97 Million USD | -10384.76% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -1212.82% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -687.191% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -434.148% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -3537.77% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -16445.262% |
| Akari Therapeutics, Plc | 16.8 Million USD | -7997.209% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -59743.226% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -354.639% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -20123.98% |
| UroGen Pharma Ltd. | 138.88 Million USD | -879.795% |
| Sutro Biopharma, Inc. | 243 Million USD | -459.986% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -18606.36% |
| Orgenesis Inc. | 45.75 Million USD | -2874.008% |
| Entera Bio Ltd. | 8.86 Million USD | -15259.108% |
| GH Research PLC | 41.22 Million USD | -3201.191% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -5193.36% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -1538.492% |
| Xencor, Inc. | 306.97 Million USD | -343.296% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -27482.604% |
| Replimune Group, Inc. | 234.77 Million USD | -479.631% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -6541.408% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -609.513% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -20123.98% |
| Portage Biotech Inc. | 18.19 Million USD | -7377.427% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -18645.265% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -1196.498% |
| OncoCyte Corporation | 25.63 Million USD | -5208.02% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -22224.553% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -11777.54% |
| Purple Biotech Ltd. | -22.46 Million USD | 6156.959% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -8157.385% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1987.847% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -15999.131% |
| HilleVax, Inc. | 133.34 Million USD | -920.523% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -13131.084% |
| Tharimmune, Inc. | 9.45 Million USD | -14292.23% |
| Genprex, Inc. | 31.06 Million USD | -4281.173% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -625.668% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -4236.989% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -177784.575% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -24883.243% |
| OKYO Pharma Limited | 8243.57 USD | -16507517.452% |
| Savara Inc. | 15.74 Million USD | -8542.852% |
| Curis, Inc. | 58.35 Million USD | -2231.963% |
| Daré Bioscience, Inc. | 33.6 Million USD | -3948.918% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -26622.046% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -18139.07% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -4935.96% |
| BeiGene, Ltd. | 3.28 Billion USD | 58.595% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -6724.798% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -172.837% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -785.649% |
| Erasca, Inc. | 141.52 Million USD | -861.538% |
| bluebird bio, Inc. | 240.23 Million USD | -466.46% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -29960.19% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 22.073% |
| DBV Technologies S.A. | 92.16 Million USD | -1376.581% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -29960.19% |
| Moderna, Inc. | 6.39 Billion USD | 78.717% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -3093.731% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -9372.484% |
| Molecular Templates, Inc. | 63.09 Million USD | -2056.911% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1940.175% |
| Travere Therapeutics, Inc. | 472 Million USD | -188.307% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -849.555% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -2091.967% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -3034.512% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -553.83% |
| MacroGenics, Inc. | 217.21 Million USD | -526.484% |
| RenovoRx, Inc. | 11.39 Million USD | -11841.181% |
| Adicet Bio, Inc. | 152.03 Million USD | -795.051% |
| Prime Medicine, Inc. | 186.63 Million USD | -629.117% |
| Aditxt, Inc. | 25.95 Million USD | -5143.842% |
| Adagene Inc. | 41.83 Million USD | -3153.103% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -18515.578% |
| Quantum-Si incorporated | 111.65 Million USD | -1118.726% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -691.863% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -9234.879% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -3698.83% |
| SciSparc Ltd. | 9.01 Million USD | -15001.731% |
| Vericel Corporation | 142.04 Million USD | -858.052% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -15619.878% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -5793.893% |
| Generation Bio Co. | 144.46 Million USD | -841.957% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -1538.946% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -1473.927% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -360.171% |
| Invivyd, Inc. | 205.75 Million USD | -561.377% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -1785.859% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -14409.958% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -1708.299% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -13128.512% |
| 2seventy bio, Inc. | 289.88 Million USD | -369.43% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1943.698% |
| Clene Inc. | 41.07 Million USD | -3213.167% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -10524.837% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -2383.424% |
| GeoVax Labs, Inc. | 6.02 Million USD | -22496.777% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -286.543% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -3604.716% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -3934.68% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -1212.238% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -4075.694% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -699.174% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -77.254% |
| Evaxion Biotech A/S | 22.27 Million USD | -6010.539% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -903.967% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -479.362% |
| Trevena, Inc. | 38.41 Million USD | -3442.595% |
| Surrozen, Inc. | 18.55 Million USD | -7235.941% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -1602.192% |
| Cingulate Inc. | 22.75 Million USD | -5879.198% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 18263.601% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2946.582% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -16426.922% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -1226.876% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -80.459% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -2092.25% |
| Clearmind Medicine Inc. | 8.74 Million USD | -15467.584% |
| Kronos Bio, Inc. | 128.11 Million USD | -962.159% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -1518.633% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -46296.998% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1249.655% |
| Statera Biopharma, Inc. | 28.82 Million USD | -4620.223% |
| ImmunityBio, Inc. | 362.87 Million USD | -275.013% |
| Korro Bio, Inc. | 84.53 Million USD | -1509.787% |
| Kineta, Inc. | 21.15 Million USD | -6332.298% |
| BioVie Inc. | 31.95 Million USD | -4159.18% |
| Codexis, Inc. | 66.51 Million USD | -1945.788% |
| Celularity Inc. | 215.05 Million USD | -532.767% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -500.481% |
| Celcuity Inc. | 66.23 Million USD | -1954.673% |
| Virax Biolabs Group Limited | 6.54 Million USD | -20685.152% |
| Cibus, Inc. | 320.3 Million USD | -324.85% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -3064.691% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -3920.852% |
| IN8bio, Inc. | 30.33 Million USD | -4385.668% |
| Kodiak Sciences Inc. | 277.32 Million USD | -390.701% |
| Annexon, Inc. | 143.72 Million USD | -846.833% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -966.546% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -5840.098% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -212527.656% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -74.556% |
| Eyenovia, Inc. | 25.4 Million USD | -5256.188% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -869.83% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -24366.325% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -1619.658% |
| Arcellx, Inc. | 200.19 Million USD | -579.732% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -2864.743% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -528.811% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -13566.938% |
| Moolec Science SA | 52.75 Million USD | -2479.718% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -2125.812% |
| Geron Corporation | 70.44 Million USD | -1831.854% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -2823.973% |
| Royalty Pharma plc | 862.4 Million USD | -57.793% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -1346.57% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -14488.728% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -5913.722% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -554.831% |
| Humacyte, Inc. | 23.49 Million USD | -5691.45% |
| Structure Therapeutics Inc. | 102.77 Million USD | -1224.074% |
| 89bio, Inc. | 151.2 Million USD | -799.987% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -1598.219% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -9259.127% |
| Genelux Corporation | 24.33 Million USD | -5492.016% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -3911.488% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -687.196% |
| Notable Labs, Ltd. | 14.77 Million USD | -9113.385% |
| Liquidia Corporation | 87.98 Million USD | -1446.664% |
| Mustang Bio, Inc. | 48.5 Million USD | -2705.75% |
| Immunovant, Inc. | 282.7 Million USD | -381.349% |
| Quantum-Si incorporated | 111.65 Million USD | -1118.726% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -5936.271% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -6298.726% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -1233.977% |
| Acasti Pharma Inc. | 11.3 Million USD | -11941.563% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -5836.961% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -8416.091% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -2823.847% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -119840.154% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -8466.14% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -4567.205% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -3188.268% |
| PepGen Inc. | 84.76 Million USD | -1505.381% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -4492.545% |
| United Therapeutics Corporation | 885.1 Million USD | -53.747% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -5843.211% |
| Solid Biosciences Inc. | 104.31 Million USD | -1204.527% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -4058.273% |
| Immuneering Corporation | 58.41 Million USD | -2229.652% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -26633.869% |
| Silo Pharma, Inc. | 3.92 Million USD | -34598.291% |
| Belite Bio, Inc | 31.66 Million USD | -4197.136% |
| XOMA Corporation | 46.46 Million USD | -2828.819% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1914.533% |
| Bionomics Limited | 17.89 Billion USD | 92.394% |
| Apogee Therapeutics, Inc. | 93 Million USD | -1363.197% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 3913.949% |
| uniQure N.V. | 285.08 Million USD | -377.336% |
| Cassava Sciences, Inc. | 105.95 Million USD | -1184.311% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -18515.578% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -600.704% |
| Forte Biosciences, Inc. | 32.47 Million USD | -4090.095% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -16278.11% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -4529.417% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -24366.325% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -9476.474% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -15209.0% |
| Altimmune, Inc. | 30.55 Million USD | -4353.518% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -218.207% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 3913.949% |
| Compugen Ltd. | 43.97 Million USD | -2994.806% |
| Peak Bio, Inc. | 1249.13 USD | -108941083.063% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -1735.965% |
| Benitec Biopharma Inc. | 22.38 Million USD | -5979.962% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -459.572% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -4667.603% |
| Zura Bio Limited | 62.63 Million USD | -2072.51% |
| PolyPid Ltd. | 21.04 Million USD | -6366.225% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -8260.881% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -4667.603% |
| Instil Bio, Inc. | 85.78 Million USD | -1486.311% |
| argenx SE | 1.53 Billion USD | 11.262% |
| Immunome, Inc. | 122.82 Million USD | -1007.977% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -2707.371% |
| Verona Pharma plc | 67.15 Million USD | -1926.495% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -5157.164% |
| Shattuck Labs, Inc. | 93.61 Million USD | -1353.647% |
| CervoMed Inc. | 14.95 Million USD | -8997.728% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1824.695% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -15827.165% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -2568.269% |
| Moolec Science SA | 52.75 Million USD | -2479.718% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -8173.228% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -926.605% |
| AnaptysBio, Inc. | 181.56 Million USD | -649.481% |
| Design Therapeutics, Inc. | 78.19 Million USD | -1640.398% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -1463.421% |
| NeurAxis, Inc. | 8.82 Million USD | -15326.667% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -10713.008% |
| Lumos Pharma, Inc. | 38.66 Million USD | -3419.506% |
| Achilles Therapeutics plc | 75.25 Million USD | -1708.275% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -5157.164% |
| 180 Life Sciences Corp. | 13.47 Million USD | -9996.954% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -5034.685% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -46296.998% |
| Nutriband Inc. | 5.73 Million USD | -23632.292% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -1128.396% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -2345.182% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -2574.614% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1958.756% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -2414.3% |
| Palisade Bio, Inc. | 13.32 Million USD | -10116.344% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -2896.8% |
| Beam Therapeutics Inc. | 554.19 Million USD | -145.549% |
| Neurogene Inc. | 55.58 Million USD | -2348.261% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -447.637% |
| AEON Biopharma, Inc. | 48.42 Million USD | -2709.922% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -1307.111% |
| Sesen Bio, Inc. | 78.38 Million USD | -1636.157% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -1529.155% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -10711.379% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -201.738% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -1448.318% |
| Athira Pharma, Inc. | 125.46 Million USD | -984.61% |
| Vaccinex, Inc. | 23.45 Million USD | -5701.821% |
| HCW Biologics Inc. | 21.02 Million USD | -6371.6% |
| XOMA Corporation | 46.46 Million USD | -2828.819% |
| Nektar Therapeutics | 190.9 Million USD | -612.832% |
| Arvinas, Inc. | 480 Million USD | -183.504% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -59743.226% |
| Merus N.V. | 200.49 Million USD | -578.732% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -1216.644% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -3830.725% |
| Rezolute, Inc. | 70.38 Million USD | -1833.336% |
| Clene Inc. | 41.07 Million USD | -3213.167% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -8208.57% |
| BeyondSpring Inc. | 24.86 Million USD | -5372.821% |
| Synlogic, Inc. | 58.53 Million USD | -2224.911% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -7505.729% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -30194.234% |
| Peak Bio, Inc. | 1249.13 USD | -108941083.063% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -2151.294% |
| Krystal Biotech, Inc. | 160.42 Million USD | -748.252% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -402.831% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -290.997% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -62996.191% |
| MannKind Corporation | 125.59 Million USD | -983.479% |
| Ikena Oncology, Inc. | 84.57 Million USD | -1508.968% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -14006.116% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -1418.752% |
| Gossamer Bio, Inc. | 183.75 Million USD | -640.544% |
| CohBar, Inc. | 12.38 Million USD | -10884.698% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -2582.787% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -4833.714% |
| Legend Biotech Corporation | 583.14 Million USD | -133.358% |
| Mural Oncology plc | 192.07 Million USD | -608.497% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1926.624% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -8328.579% |
| Disc Medicine, Inc. | 91.12 Million USD | -1393.352% |
| Champions Oncology, Inc. | 28.11 Million USD | -4741.042% |
| REGENXBIO Inc. | 321.15 Million USD | -323.723% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -25282.533% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2340.665% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -3392.799% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -1089.973% |
| Vaxart, Inc. | 90.72 Million USD | -1399.92% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -15872.016% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -3079.919% |
| Cellectis S.A. | 97.32 Million USD | -1298.291% |
| Longeveron Inc. | 21.25 Million USD | -6303.845% |
| Repare Therapeutics Inc. | 167.35 Million USD | -713.122% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -1698.952% |
| Revolution Medicines, Inc. | 498.76 Million USD | -172.837% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -20357.261% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -2996.003% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -1724.396% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1854.214% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -12203.951% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 71.501% |
| Denali Therapeutics Inc. | 527.23 Million USD | -158.107% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -15619.878% |
| Veru Inc. | 101.34 Million USD | -1242.715% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -5713.718% |
| Cingulate Inc. | 22.75 Million USD | -5879.198% |
| Passage Bio, Inc. | 108.38 Million USD | -1155.494% |
| Context Therapeutics Inc. | 25.07 Million USD | -5327.503% |
| Exicure, Inc. | 14.07 Million USD | -9567.64% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -560.386% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -3042.692% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -14728.092% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -438.974% |
| Nuvalent, Inc. | 149.49 Million USD | -810.294% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -16769.14% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -1212.896% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -6244.431% |
| OmniAb, Inc. | 83.89 Million USD | -1522.048% |
| Anew Medical, Inc. | 1.3 Million USD | -104510.556% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -4053.391% |
| Lipocine Inc. | 15.08 Million USD | -8923.902% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1886.217% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -1686.975% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -3275.518% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -1084.937% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -5979.418% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -104.898% |
| Ocugen, Inc. | 71.56 Million USD | -1801.459% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -1349.744% |
| Q32 Bio Inc. | 92.68 Million USD | -1368.296% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -6326.83% |
| Alumis Inc. Common Stock | 158.17 Million USD | -760.329% |
| Equillium, Inc. | 50.6 Million USD | -2589.043% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -2080.587% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -9686.139% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -7113.407% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -2798.377% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -1154.602% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -10880.771% |
| Dominari Holdings Inc. | 23.83 Million USD | -5609.322% |
| Edesa Biotech, Inc. | 9.22 Million USD | -14654.99% |
| vTv Therapeutics Inc. | 11.9 Million USD | -11328.714% |
| Bio-Techne Corporation | 563.03 Million USD | -141.691% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -232.876% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -406.339% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -928.763% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -9342.905% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -731.307% |
| Nkarta, Inc. | 131.65 Million USD | -933.663% |
| BioCardia, Inc. | 12.12 Million USD | -11126.937% |
| Iterum Therapeutics plc | 47.46 Million USD | -2766.809% |